A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States

Appl Radiat Isot. 2008 Feb;66(2):252-60. doi: 10.1016/j.apradiso.2007.09.002. Epub 2007 Sep 18.

Abstract

A blind performance test was conducted to evaluate dose-calibrator measurements at nuclear pharmacies in the United States (US). Two test-sample geometries were chosen to represent those used for measurements of 90Y-ibritumomab tiuxetan (ZEVALIN). The radioactivity concentration of test-samples was verified by the US National Institute of Standards and Technology. Forty-five results were reported by 10 participants. Eighty percent of reported values were within the US Pharmacopoeia content standard (+/-10%) for 90Y-ZEVALIN. All results were within US Nuclear Regulatory Commission conformance limits (+/-20%) for defining therapeutic misadministrations.

Publication types

  • Evaluation Study

MeSH terms

  • Ambulatory Care Facilities / standards
  • Antibodies, Monoclonal / analysis*
  • Antibodies, Monoclonal / therapeutic use
  • Humans
  • Neoplasms / radiotherapy
  • Nuclear Medicine / standards
  • Pharmacies / standards
  • Pilot Projects
  • Quality Control
  • Radioimmunotherapy
  • Radiometry / methods
  • Radiometry / standards
  • Radiopharmaceuticals / analysis*
  • Radiopharmaceuticals / standards
  • Radiopharmaceuticals / therapeutic use
  • Radiotherapy Dosage
  • Reference Standards
  • United States
  • Yttrium Radioisotopes / analysis*
  • Yttrium Radioisotopes / standards
  • Yttrium Radioisotopes / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan